Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12665781 | 0.89 | CYP1A2 (0.47) | CYP1A2L3MBTL1CYP2C9CYP2C19POLB | |
| SCHEMBL1863009 | 0.87 | MEN1 (0.58) | CYP1A2L3MBTL1CYP2C9CYP2C19POLB | |
| SCHEMBL12660795 | 0.84 | CYP1A2 (0.61) | CYP1A2L3MBTL1CYP2C9CYP2C19POLB | |
| SCHEMBL12666802 | 0.81 | CYP1A2 (0.68) | CYP1A2L3MBTL1CYP2C9CYP2C19POLB | |
| SCHEMBL7373877 | 0.79 | ELANE (0.53) | CYP1A2L3MBTL1CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL1862789 | 0.78 | CHRNB2 (0.49) | CYP1A2CYP2C19POLBALDH1A1KDM4E | |
| SCHEMBL5119871 | 0.77 | CYP1A2 (0.66) | CYP1A2L3MBTL1CYP2C9CYP2C19POLB | |
| SCHEMBL22832828 | 0.77 | KDM4E (0.45) | CYP1A2L3MBTL1CYP2C9CYP2C19POLB | |
| SCHEMBL1865850 | 0.76 | GRM5 (0.45) | CYP1A2CYP2C9CYP2C19ALDH1A1MAPK1 | |
| SCHEMBL3228832 | 0.76 | DCTPP1 (0.64) | CYP1A2L3MBTL1CYP2C9CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493877-B1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-17 | — | — | EP | disclosed |
| EP-2493877-B1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-17 | — | — | EP | disclosed |
| US-20130310358-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-11-21 | — | — | US | disclosed |
| US-8513271-B2 | Pyrimidine compounds as delta opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-20 | — | — | US | disclosed |
| US-8513271-B2 | Pyrimidine compounds as delta opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-20 | — | — | US | disclosed |
| EP-2493877-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2012-09-05 | — | — | EP | disclosed |
| US-20110105520-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2011-05-05 | — | — | US | disclosed |
| WO-2011053705-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
| US-20110105520-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105520-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | OPRD1, OPRK1, OPRM1 | CYP1A2 561/4885L3MBTL1 825/4885CYP2C9 1033/4885 |
| US-20130310358-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | OPRD1, OPRK1, OPRM1 | CYP1A2 561/4885L3MBTL1 825/4885CYP2C9 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.